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Human epidermal cell cultures were used to study the effects 
of retinoids on keratinocyte differentiation. Keratin profiles 
Were studied by quantitative gel electrophoresis of culture 
extracts, whereas the extent of envelope formation was as-
sessed in an enzyme-linked immunosorbent assay (ELISA) 
USlllg an antibody that specifically recognizes keratinocyte 
envelopes. Exposure of cultures to a variety of different reti-
nOlds produced both dose-dependent decreases in keratin 16 
wI~h consequent increases in the keratin 14: keratin 16 
rat~o~ and a decrease in envelope formation. The order of 
actiVity in both assays was similar: arotinoid ethyl ester (Ro 
13-6298) ~ arotinoid acid (Ro 13-7410) ~ all trans reti-
noic acid (Ro 1-5488) > acitretin (Ro 10-1670) 2: etretinate 
(Ro 10-9359), the only difference being that acitretin was 
slightly more active than etretinate in the keratin assay 
whereas these retinoids were equi-active in the envelope 
assay. Analysis of the lesional keratins of psoriasis patients 
showed that etretinate caused a reduction in keratin 16 and an 
increase in the keratin 14: keratin 16 ratio, although the 
magnitude of these changes and their correlation with clini-
cal improvement was variable. As the in vitro assays reported 
here are simple and quick, they allow rapid screening of 
compounds for retinoid-like activity. ] [ntlest Dermatol 
99:95-100,1992 
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Psoriasis is a common skin disease in which the cutaneous lesions are characterized by benign epidermal hyper-plasia, abnormal differentiation, inflammation, and changes in the dermal vasculature. Studies of epidermal h differentiation in the psoriatic lesion have shown 
c ~nges in the keratin profile [1-6], involucrin distribution [7 -9], 
an ~nvelope type [10 -12], such that the lesional epidermal pheno-
type IS remarkably similar to that seen in wound skin [13] . Keratins 1 
a.nd 10 are variably reduced or absent, whereas the "hyperprolifera-
tlon ma~ler" keratins 16 and 6 are often expressed [3,5,6]. Envelope 
syntheSIS OCcurs precociously and the envelopes formed are differ-
~nt from those seen in normal, interfollicular epidermis. However, 
unng clinical resolution of the lesions under a variety of treat-
~tnts, the keratin profiles and the epidermal morphology eventu-
a y normalize [15]. 
A great variety of treatments exists for psoriasis, generally based 
.On antI-proliferative, anti-inflammatory, or differentiation-modify-
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rev latIOns: 
OTT: dithiothreitol 
~GF: epidermal growth factor 
F LISA: enzyme-linked immunosorbent assay 
CS: fetal calf serum 
~s: phosphate-buffered saline 
: All trailS retinoic acid 
SDS: sodium dodecyl sulphate 
ing strategies, or a combination of two or more approaches. The 
retinoid, etretinate, and more recently, acitretin and arotinoid, have 
shown considerable efficacy in treatment of severe recalcitrant psori-
asis [16 - 21]. Although their exact modes of action are uncertain, it 
is likely that their anti-inflammatory properties and their effects on 
proliferation and differentiation are important [22 - 24]. To date, 
retinoids used clinically have been identified by an in vivo screening 
procedure using the mouse anti-papilloma model [25]. Though ef-
fective, this screen is time consuming and expensive, both in terms 
of animals used and the amount of test compounds required. Reti-
noid effects have also been investigated in a number of in vitro 
systems, including keratinocyte cultures, where both changes in the 
keratin profile [26 - 32] and inhibition of cell envelope formation 
have been observed [33 - 35]. 
With respect to the keratins, retinoids induce the expression of 
K13 and K19 [27-29] and inhibit the expression ofKl, KI0, K6, 
and K16 [26,27,30]. In principal, assays (or detecting and measuring 
retinoid-like activity could be based on any consistent retinoid-in-
duced change in the keratin profile [31,35,36]. However, we have 
chosen to use the effect of retinoids on the ratio of K14: K16 as a 
criterion for activity in our assay. Keratin 14 gene transcription 
occurs mainly in the basal cells and is down regulated in the supra-
basal layer [37-38], whereas K16 is expressed suprabasally and is 
frequently, though not inevitably, associated with hyperprolifera-
tion [6,30,32]. Changes in the ratio of these keratins may therefore 
provide both information about the influence of retinoids on the 
differentiation state and an indication of their influence on prolifera-
tion. 
In conjunction with this approach, we have also developed an 
assay for retinoid activity based on the inhibition of expression of 
another major product of keratinocyte differentiation; the cell en-
velope [34,35]. 
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MATERIALS AND METHODS 
Epidermal cells were isolated from human skin biopsies after initial 
dermal-epidermal separation with dispase [39] and cultured on 3T3 
cell feeder layers as previously described [40]. For the analysis of 
keratins and envelopes, S X 103 or 104 epidermal cells, respectively, 
were added to each well of 48-well plates containing feeder layers. 
The medium used initially was 1: 1 Ham's F12 and Dulbecco's 
modified Eagle's medium with normal Ca++ levels, glutamine 
(2 mM) and antibiotics, supplemented with O.4l1g/ml hydrocorti-
sone, 20 ng/ml EGF, 10 I1g/ml transferrin, 10 I1g/ml insulin, 10 
ng/ml cholera toxin, 10 ng/ml selenium ions, and 5% FCS. On day 
3, when small keratinocyte colonies had developed, the medium 
was changed to medium without FCS but otherwise of the same 
composition (6F medium) and test retinoids were introduced. Me-
dium was changed three times a week with fresh retinoids being 
added each time. Unless otherwise stated, cultures were harvested 
on day 16. 
Keratin Extraction and Analysis Cultures for keratin analysis 
were harvested at varying times by removing the medium, rinsing 
with PBS, adding 0.2 ml 2% SDS, 20 mM DTT per well, and 
heating the plate, sealed with tape, at 80°C for 15 min with gentle 
agitation. Protein concentrations were determined using the modi-
fied Lowry assay [41] and electrophoresis was carried out on 7.5% 
SDS polyacrylamide gels [42]. After electrophoresis, gels were 
stained with Coomassie Blue and individual keratin polypeptides 
quantitated using a Chromoscan 3 scanning densitometer (Joyce 
Loebl). 
Keratins were also extracted from keratotome biopsies of psori-
atic lesions taken from patients before and during treatment with 
oral adm inistration of 0.75 mg etretinate/kg body weight/d, as 
previously described [15]. Patients on this therapy had severe psoria-
sis and had failed to respond adequately to other treatments. No 
A 
B 
Figure 1. E33 epidermal keratinocytes. (A) Control culture. (B) Culture 
treated with 10-6 M RA. Culture time, 18 d. Magnification X 56. 
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Figure 2. Effects of RA on the culture keratin profiles of three different 
keratinocyte strains, E18, E32, and E33. Lalles 1, 3, and 5 are extracts of 
control cultures not exposed to RA; lanes 2, 4 and 6 are extracts from cultures 
treated with 10- 6 M RA. 
other treatment was given during the course of the etretinate ther-
apy. Quantification was similar to that described for the culture 
extracts except that 7.5 - 17% gradient gels were used and phospho-
rylase a was added to each extract as an internal standard before 
electrophoresis. Normalized molar ratios were then calculated fronl 
the densitometry data for each keratin polypeptide as described 
previously [15]. 
Quantitation ofKeratinocyte Envelopes The extent of enve-
lope formation was determined in 11-14 d cultures using a mouse 
monoclonal antibody (9WD) raised against cultured keratinocyte 
envelopes in a standard ELISA assay. As well as recognizing culture-
type envelopes, this antibody also recognizes envelopes in psoriatiC 
lesions, wound skin, and the infrainfundibular region of hair folli-
cles, but not those of the normal interfollicular epidermis of normal 
and uninvolved psoriatic skin [11,12] . Briefly, cultures for envelope 
quantification were rinsed in PBS, fixed and permeabilized in meth-
anol/acetone (1: 1), and then air dried. The cultures were rehy-
drated in PBS, incubated with the anti-envelope antibody at 37°C 
for 1 h, then, after further washing, were incubated with a sheep 
anti-mouse p-galactosidase -linked IgG F(ab')2 fragment (Amer-
sham International) . The cultures were washed again before incU-
bation with 0 nitrophenyl-p-D-galactopyranoside and finally the 
amount of o-nitrophenol released was measured spectrophotometrl-
cally using a Titertek multiscanner. 
Direct determination of the percentage of cell envelopes formed 
in cultures was achieved by trypsinizing the cultures, counting the 
cells, then heating an aliquot of each suspension in a final concen-
tration of2% SDS, 20 mM DTT at 100°C for 2 min before count-
ing the envelopes using a hemocytometer and phase-contrast mI-
croscopy [34]. 
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RESULTS 
Retinoid Effects on Culture Morphology and Keratin Pro-
files Cultures of the epidermal keratinocyte strains used grew 
~apld l y in 6F medium, usually achieving confluence and developing 
[ocal areas of stratification between 10 and 14 d. With longer cul-
ture times, stratification became more extensive both in terms of 
area and number of suprabasallayers (Fig la) . In contrast, keratino-
cytes Cultured in 6F medium containing RA showed characteristic 
morphologic changes, beginning at about 3 X 10-8 M and becom-
I~g Increasingly obvious up to 3 X 10-6 M, the highest concentra-
tllon tested. The cells appeared more rounded, had reduced intercel-
ular contact, and there was increased desquamation with 
consequent reduction in stratification. Keratinocyte growth in cul-
tures treated with RA concentrations greater than 10-7 M was gen-
brally less well organized (Fig Ih). In addition, growth was 110ticea-
Iy retarded by RA concentrations greater than 10-7 M and with 
c?ncentrations of 10-6 M and above, confluence rarely occurred. 
Similar morphologic changes and anti-proliferative effects were 
seen with the highest concentrations of all the other retinoids 
tested. 
T he keratin profiles from cultures exposed to 10-6 M RA showed 
mar~ed changes compared with the controls and these changes were 
consistent between different epidermal cell strains (Fig 2). The rei a-
~\ve amounts of 40-kD and 46-kD proteins increased and Western 
ttting using AEll AE3 antibodies demonstrated that at least some 
o these proteins were keratins, probably K17, K18, and K19 (data 
ht shown). Quantification of these changes was difficult because of 
\ e low level of expression, particularly at RA concentrations less 
t an 10-7 M. However, RA did cause a measurable decrease in the 
relative amount of K16 (48kD), whereas K14 (50 kD) remained 
~nchanged or increased slightly, so that the ratio of K14: K16 was 
Increas~d markedly (Fig 3). This RA-induced effect has been ob-
~erv~d In all five keratinocyte strains studied, is easily quantifiable by 
enmometry, and shows good reproducibility between different 
ehpenm~nts. Interestingly, the magnitude of the RA-induced 
c jnge In the K14: K16 ratio increased with increasing time in 
~) ~re due to a reduction in this ratio in older control cultures (Fig 
. he reason for the decrease in the K 14: K 16 ratio with culture (3e is unknown but it correlated with a reduction in K14 expression 
t ata not shown) that may be associated with the increased culture s ratlfic t' b d h I I . I 01 a lon, ecause at 9 t e cu tures were a most entire y mon-
t ayers, whereas by 30 d, many cell layers had developed. In con-
;ast, cultures treated with RA showed much less stratification. 
rom a practical point of view, the amplitude of the RA effect on 
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Figure 4. Changes in the keratin 14: 16 ratio with increasing time in 
culture . Solid triallgles, controls; solid circles, cultures treated with 10-6 M RA. 
Error bars, standard deviation. 
K14: K16 at 9 d was not sufficient for reliable measurement, but by 
day 16 measurement of this effect was both reliable and accurate. 
A series of retinoids was tested in this assay and all produced 
qualitatively similar changes in the keratin profile. The dose-re-
sponse effects of the different retinoids on K14: K16 are shown in 
Fig 5 and Table I. Arotinoid ethyl ester and arotinoid acid were by 
far the most active, having ECso values of 0.25 nM and 0.4 nM, 
respectively. Compared with these, RA was about 100 times less 
potent. The order of activity of retinoids tested in this assay is as 
fo llows: arotinoid ethyl ester (Ro 13-6298) ;::0: arotinoid acid (Ro 
13-7410) ~ RA (Ro 1-5488) > acitretin (Ro 10-1670);;:' etre-
tinate (Ro 10-9359);;:' retinyl acetate (Ro 1-5275) . 
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Figure 5. Dose-response effects of retinoids on the keratin 14: 16 ratio. 
OpCll box, RA; solid circle, etretinate; opw circle, acitretin; solid dialllolld, arotin-
oid ethyl ester; opw dialllolld, arotinoid acid; solid box, retinyl acetate; asterisk, 
controls. Error bars, standard deviation. 
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Table I. The Effect of Retinoids on the Keratin 14: Keratin 16 
Ratio and on Envelope Formation in Cultured 
Retinoid 
Retinyl acetate 
Etretinate 
Acitretin 
Retinoic acid 
Arotinoid acid 
Arotinoida 
• Ethyl ester derivative. 
, ND, not determined. 
Human Keratinocytes 
Increase in K14: K16 
ECso (nM)' 
1000 
760 ± 314 
290,210 
63.4 ± 29.1 
0.4 
0.253 ± 0.076 
( Errors are standard deviations. 
Inhibition of Envelope 
Formation, ICso (nM)' 
NDb 
68.3 ± 32.5 
83.5 ± 37.5 
6.55 ± 2.55 
0.15 ± 0.02 
0.054 ± 0.031 
Retinoid Effects on Envelope Formation The effect of RA 
on cell envelope formation was initially assessed by direct counting 
and subsequently by an ELISA assay. Both methods show a compara-
ble RA dose-dependent decrease in envelope formation, but because 
the ELISA method is a much more rapid procedure, and probably 
more accurate, it has been used to generate the data reported here. 
The effects of several different retinoids were studied on three kera-
tinocyte strains and each responded with a comparable dose-depen-
dent inhibition of envelope formation for any given retinoid. The 
data for this retinoid effect are shown in Table I and Fig 6. Similar to 
their effect in the K14: K16 assay, arotinoid ethyl ester and arotin-
oid acid were about 120 times and 40 times more active than RA, 
respectively, whereas etretinate and acitretin were about 10 times 
less active. Interestingly, retinoids were more potent in inhibiting 
envelope formation than in altering the K14: K16 ratio, suggesting 
that retinoid effects on these two aspects of differentiation are not 
inevitably linked. Apart from acitretin, which was slightly more 
active than etretinate in the keratin assay, the order of activity of 
retinoids tested in both assays is the same. 
Keratin Profiles of Psoriatic Lesions Before and During 
Treatment with Etretinate For purposes of comparison with 
retinoid effects on keratins from keratinocyte cultures, we exam-
ined the effect of etretinate on the keratin profile of psoriatic lesions. 
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Figure 7. Effects of etretinate on the psoriatic lesional K 14: K 16 ratio 
during treatment. Patients were given 0.75 mg etretinate/kg body weight/ 
d. Squares, patient FR; circles, patient HO; diamollds, patient GO; triat'gles, 
patient LE. Filled symbols, time over which the greatest clinical improvement 
was seen. Error bars, standard deviation. 
Four adult patients with a long history of the disease were studied 
and all achieved good but not complete resolution of the lesions 
during the course of treatment. The major keratin changes in these 
patients' lesions include an increase and eventual over-expression of 
K1 and K10 and a reduction in K14, K16, and K18, as previously 
reported in detail [15]. The changes in the K14: K16 ratio for the~e 
patients are shown in Fig 7 and the graph symbols are filled III 
between the times when the greatest clinical improvement was 
seen. In all patients the K14: K16 ratio increased during treatmellt, 
although in patients GO and LE it peaked and then started to drop, 
returning almost to its initial value for patient LE. The correlatio? 
between an increasing K14: K16 ratio and clinical improvement IS 
particularly good for patients GO and HO. Moreover, the decrease 
in this ratio in patient GO between 17 and 27 weeks was accompa-
nied by a perceptible clinical deterioration. In contrast, however, 
this correlation was not so good for patients FR and LE because 
patient FR showed a marked increase in the K 14 : K 16 ratio that waS 
not accompanied by any obvious clinical improvement, whereaS 
during apparent clinical improvement between 20 and 27 weeks for 
patient LE, there was actually a small fall in the K14: K16 ratio. 
DISCUSSION 
The effectiveness of retinoids in treating acne, psoriasis, and some 
other skin diseases is well documented, but side effects, including 
the symptoms of hypervitaminosis A, and particularly teratogeniC-
ity, have restricted their use. The search for similar compounds With 
better therapeutic indices would be greatly facilitated by rapid, sen-
sitive in vitro assays, because the retinoids used clinically were iden-
tified in long-term animal screens. Because of the pleiotropic effectS 
of retinoids [43], new screens must be relevant to the disease target. 
We therefore assayed retinoid effects in cultured keratinocytes b~­
cause of their similarity, in several respects, to epidermal cells 1.11 
psoriatic plaques. Like lesional epidermal cells, the cultured kera~l­
nocytes are in a hyperproliferative state and have a similar keratin 
profile in lacking K1 and K10 and expressing K6 and K16 . Inv?lu-
crin expression occurs in all suprabasal cells in cultured keratlno-
cytes [44,45] and in most of the suprabasal cells in lesional Skl(l 
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[7 - 9]. This is in sharp contrast to normal or non-involved skin 
where involucrin is confined to the upper spinous and granular 
layers. Moreover, the keratinocyte envelope type in cultured cells 
and lesional skin is similar, as defined by antibody 9WD reactivity, 
but is different from that of normal or non-involved skin. 
. ~he assays reported here used the effects of retinoids on differen-
tiation as criteria for measurement of retinoid-like activity. As reti-
n?lds were added to the cultures from day 3, some of their effects on 
ddfc:rentiation may be secondary to their inhibitory effects on prolif-
eration and stratification. However, in other experiments, RA 
added to confluent, stratified cultures specifically down regulated 
K16 synthesis (data not shown), suggesting a direct effect on the 
expression of this keratin. Because K16 is not expressed in the nor-
~al epidermis, a retinoid-induced decrease in K16, with consequent 
lUerease in the K14: K16 ratio, represents a shift towards a more 
no:mal epidermal keratin profile. Further confidence in using this 
ratio. as an assay criterion would be gained if psoriasis patients im-
Phovln.g on etretinate therapy also showed a concomitant increase in 
~ e leslOnal K14: K16 ratio. Although the number of patients stud-
Ihd Was small and there was some variation in response, all patients 
~h Owed a reducti?n in.K 16 during treatment [15] and a~ increase in 
· e K14 : K 16 raUo. It IS not clear why the K 14: K 16 raUo decreased 
IU two patients (GO and LE) after an initial increase although it may 
represent the emergence of a refractory lesional state because etre-
tYlate Often induces initial improvements but fails to produce com-
Ph:te remission. Also, little is known about the temporal relation-
s riP. between the appearance of a biochemical abnormality and I/llieal manifestations and biochemical normalization may lag be-
IUd clinical resolution in some patients, as has been previously 
noted [15] . 
· All the retinoids used in this study caused a dose-related decrease 
If K16 ~nd there were no qualitative differences between the effects ~ the different retinoids on the keratin profile. This is in contrast ~o 
orge et al [32], who claim a distinction between non-aromaUc 
~tlUoids and polyaromatic retinoids with respect to their effects on 
· ~4. They also report that low and high concentrations of RA 1\ Uce and inhibit K16 expression, respectively. However, the sig-
kl ea.nee of their data is difficult to assess because many of the 
eratln changes are small, only single values are given, and at least 
Sorne of the results were obtained from scanning immunoblots that 
:he .notoriously difficult to quantitate. Moreover, interpretation of 
. elr results is further complicated by the apparent use of non-deli-
Plzed serum in their culture medium, containing an unknown 
arnount of retinol and retinoic acid, which may account for the K13 
eXpression in their control cultures. 
hAlthough retinoids in vitro caused a reduction in K16 and a 
e a~ge in the K 14: K 16 ratio similar to that produced by etretinate 
~n v~vo, they did not induce K1 and K10 expression. In fact, para-
d OXI~ally, under culture conditions where these keratins are in-
r:;ee , retinoids inhibit their expression [26,27]. As the environ-
a ents of keratinocytes in the epidermis and in submerged cultures r~~' rather different, it is perhaps not surprising that some different 
Ii ~~Old effects are seen in the two situations. Nevertheless, the 
th lUg that retinoids both in vitro and in lesional epidermis have 
as e sam~ effect on the K14: K16 ratio is reassuring for its use as an 
sih eflteri?n for relevant retinoid-like activity. 
cyt d~orll1fied envelope is another important marker ofkeratino-for~e l~erentiation. In involved psoriatic skin, envelopes are 
res d .1n many of the upper epidermal layers and are probably 
le/onslble, at least in part, for the stiffening and cracking of the 
w~oki" T~e. value of an envelope assay in detecting an agent that 
the u £ inhibit envelope formation as part of its therapeutic effect is 
env
r1 Ore apparent. Retinoids tested in the envelope assay inhibit 
POt e ope formation with a similar rank order, but with greater l3Sf~h than their effects on the keratin profile, as noted previously 
and' . e <:mly difference was that in the envelope assay, etretinate 
in thC~retl~ are equiactive, whereas the latter is slightly more active 
cYte e ~ratln assay. This may be due to differences in the keratino-
forrnst~alns. used in the two assays. That the inhibition of envelope 
atlon IS real and not just a masking or deletion of the epitope 
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recognized by the antibody is shown by parallel studies where enve-
lopes were counted using microscopy. 
The assays developed here are somewhat similar to those of Gilfix 
and Green [35] , but have the following advantages: epidermal, 
rather than conjunctival keratinocytes were used, which are poten-
tially more relevant to psoriasis; the ELISA method of envelope 
quantification is quicker and easier than counting by microscopy; 
and, finally, quantification ofK14 and K16, which are major kera-
tins, is more accurate than that of the retinoid-inducible 40kD kera-
tin, particularly at low retinoid concentrations. Both assays produce 
rank orders of retinoid activity similar to those observed in other in 
vitro screens [35,46]. However, the order differs from those in ani-
mal screens. Arotinoid ethyl ester and arotinoid acid are still much 
more active in vivo than RA, but etretinate and acitretin are also 
generally more active than RA ([47 -49], but see [50]) . Relative 
activity in the assays described here is therefore not necessarily a 
precise indicator of relative activity in vivo. 
The recent discovery of two classes of retinoid receptor, RAR 
[51- 56] and RXR [57], means that eventually screening for new 
retinoids with improved tissue selectivity and therapeutic index by 
using specific receptor binding assays should be possible. Before this 
is practical, much more needs to be known about receptor tissue 
distribution and the significance of the different receptor isoforms 
in normal and diseased states. In the meantime, assays of the type 
described in this report will allow rapid screening for compounds 
that may be useful for the treatment of psoriasis and possibly other 
skin diseases. They would also detect compounds that could induce 
the desired phenotypic changes by retinoid-independent mecha-
msms. 
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